GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » Effective Interest Rate on Debt %

Eterna Therapeutics (Eterna Therapeutics) Effective Interest Rate on Debt % : 5.17% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Eterna Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $2.10 Mil. Eterna Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $40.72 Mil. Therefore, Eterna Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 5.17%.


Eterna Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Eterna Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eterna Therapeutics Effective Interest Rate on Debt % Chart

Eterna Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
1.48 2.63 1.54 2.85

Eterna Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 - - 1.22 5.17

Competitive Comparison of Eterna Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Eterna Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eterna Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Eterna Therapeutics's Effective Interest Rate on Debt % falls into.



Eterna Therapeutics Effective Interest Rate on Debt % Calculation

Eterna Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.614/( (1.182+41.843)/ 2 )
=-1  *  -0.614/21.5125
=2.85 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.887 + 0.295
=1.182

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=39.627 + 2.216
=41.843

Eterna Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -2.104/( (39.599+41.843)/ 2 )
=-1  *  -2.104/40.721
=5.17 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=38.45 + 1.149
=39.599

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=39.627 + 2.216
=41.843

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Eterna Therapeutics  (NAS:ERNA) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Eterna Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eterna Therapeutics (Eterna Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Executives
Dorothy J Clarke director C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder director C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft 10 percent owner 4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern 10 percent owner
Nicholas Jason Singer director 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore director 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson officer: Chief Financial Officer 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel officer: Interim President and CEO 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman director TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright director 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536

Eterna Therapeutics (Eterna Therapeutics) Headlines

From GuruFocus

Brooklyn ImmunoTherapeutics Announces Board Changes

By GuruFocusNews GuruFocusNews 06-17-2022